<DOC>
	<DOCNO>NCT00003386</DOCNO>
	<brief_summary>RATIONALE : Vaccines make tumor tissue may make body build immune response kill tumor cell . PURPOSE : Phase II trial study effectiveness vaccine therapy treat patient stage III stage IV ovarian epithelial cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether patient surgically debulked ovarian epithelial cancer develop delayed-type hypersensitivity dinitrophenyl-modified autologous tumor vaccine . II . Assess toxic effect regimen patient . III . Determine feasibility conduct group wide vaccine study . OUTLINE : Patients undergo standard debulking procedure tumor tissue send Thomas Jefferson University . Patients receive six course combination chemotherapy consist either paclitaxel cisplatin paclitaxel carboplatin . Vaccine therapy must commence within 4-12 week completion chemotherapy . Patients test delayed-type hypersensitivity ( DTH ) day -7 . Cyclophosphamide IV administer day 0 . Dinitrophenyl ( DNP ) -modified autologous ovarian epithelial cell vaccine BCG adjuvant inject week begin day 3 continue 6 week . DTH test repeat week 8 . Booster vaccine injection administer 6 12 month patient disease free . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 20 patient accrue study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Surgically debulked stage III IV ovarian epithelial cancer Must able obtain adequate number viable cell excise tumor mass Must receive 6 course combination chemotherapy comprise either paclitaxel cisplatin OR paclitaxel carboplatin Must clinically tumor free follow completion chemotherapy ( i.e. , metastasis physical examination CT abdomen pelvis serum CA125 le 35 IU/L ) Not Phase III GOG protocol PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 0 1 Hematopoietic : Hematocrit least 25 % WBC least 3,000/mm3 Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing No active infection HIV negative Hepatitis B surface antigen negative Hepatitis C antibody negative No active autoimmune disease No prior invasive malignancy within past 5 year except nonmelanomatous skin cancer , carcinoma situ cervix , superficial bladder cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics 412 week since prior chemotherapy Endocrine therapy : No concurrent systemic corticosteroid Radiotherapy : At least 6 month since prior major field radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>